Sorokin Igor, Schatz Adam, Welliver Charles
Division of Urology, Albany Medical College, Albany, NY, USA.
Curr Urol Rep. 2015 Oct;16(10):73. doi: 10.1007/s11934-015-0544-4.
Placebo medications and sham surgeries have long been thought to be inert treatments. These groups served as a threshold to which an active treatment should be compared in a randomized trial to determine the true efficacy of the active treatment. However, surprising changes in subjective symptom scores and objective measures of voiding have been demonstrated in numerous placebo medication or sham surgery arms of trials. The exact mechanisms by which these inactive treatments augment patient outcomes are not clearly defined and multiple theories have been proposed to explain the often pronounced response. It appears that urologic outcomes are particularly prone to these effects and the astute physician should keep these responses in mind when interpreting any trial on a new therapy.
长期以来,安慰剂药物和假手术一直被认为是无效治疗方法。在随机试验中,这些组作为一个基准,与积极治疗进行比较,以确定积极治疗的真正疗效。然而,在众多试验的安慰剂药物组或假手术组中,主观症状评分和排尿客观指标都出现了惊人的变化。这些无效治疗改善患者预后的确切机制尚不清楚,人们提出了多种理论来解释这种通常很明显的反应。似乎泌尿外科的预后特别容易受到这些影响,精明的医生在解读任何关于新疗法的试验时都应牢记这些反应。